Angus Russell - Shire

Angus Russell
CEO, Shire

Total Compensation: $11.924 million

Professional Profile: Angus Russell, 57, got into the pharma business by way of chemicals. After working at Pricewaterhouse Coopers for 5 years, he joined Imperial Chemical Industries, where he worked until 1993 in positions in finance, marketing and business development. From there he joined the old Zeneca and became a vice president in finance in the merged AstraZeneca ($AZN). He jumped ship for Shire ($SHPG) soon after that, first as CFO for about 9 years, and then, beginning in 2008, as CEO. He retired from that post in April 2013.

Compensation Breakdown: $1.29 million in salary, with a $9.03 million bonus, $281,000 in stock and $845,000 in incentive pay, plus $387,000 in pension benefits and $88,000 in other compensation, including a car allowance, disability coverage and private medical insurance.

Company Performance: Since he joined the company, Russell has helped shepherd Shire beyond its familiar pastures in the ADHD business. Though its ADHD franchise still delivers blockbuster sales via its newer Vyvanse treatment, Shire has snapped up one company after another to build up in rare diseases and regenerative medicine. Russell's late-stage deal strategy has won accolades, partly for his emphasis on lower-risk deals. Russell also arrived early at the orphan-drug party, moving Shire into a field that is now one of the hottest in pharma. For 2012, the numbers were strong, with $4.4 billion in sales, a 12% increase, despite generic rivals to its older ADHD drug, Adderall XR. Excluding charges, earnings were up 14% to $6.10 per share.

For more:
Special Report: Shire - The Biggest R&D Spenders in Biotech
Shire chief prepares to hand over reins to hand-picked successor
Booming Shire closes in on new campus site for U.S. HQ
Shire's Vyvanse tops $1B as more generics challenge Adderall
Shire upbeat on 2012 as earnings top estimates

Angus Russell - Shire
Read more on

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.